Response to Specialty Drugs
First written in FY2019. 4 of 7 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「Including “cancer liaisons,” “Medical MS,” which specialises in the medical device field, and the “Lab Access Department,” which strengthens approaches to pathology laboratories」
The Company has reaffirmed its approach to specialty pharmaceuticals by leveraging expertise in cancer treatments, medical devices and pathology testing. - FY2026-H1RestatedAnnual report
「As specialty pharmaceuticals become the main source of newly launched drugs, pharmaceutical wholesalers are required to further enhance their capabilities in providing information and handling logistics.」
Regarding specialty pharmaceuticals, the Company has reaffirmed its market view that newly launched drugs are shifting towards this field, as well as the need to further enhance information-provision and logistics capabilities. - FY2026-H1RestatedAnnual report
「As specialty pharmaceuticals become the main source of newly launched drugs, pharmaceutical wholesalers are required to further enhance their capabilities in providing information and handling logistics.」
Regarding specialty pharmaceuticals, the Company has reaffirmed its market view that newly launched drugs are shifting towards this field, as well as the need to further enhance information-provision and logistics capabilities. - FY2022RestatedAnnual report
「The Company is actively pursuing the expansion of new businesses, including undertaking distribution operations for specialty pharmaceuticals from May 2021 in response to changes in drug discovery modalities.」
The Company continues to undertake distribution operations for specialty pharmaceuticals in response to changes in drug discovery modalities. - FY2021AdvancedAnnual report
「The Company is actively pursuing the expansion of new businesses, including undertaking distribution operations for specialty pharmaceuticals from May 2021 in response to changes in drug discovery modalities (Note 5).」
Regarding specialty pharmaceuticals, the Company shows concrete progress in undertaking distribution operations from May 2021 in response to changes in drug discovery modalities. - FY2020AdvancedAnnual report
「The Company focused on sales to hospitals of antineoplastic drugs and specialty pharmaceuticals, centred on “cancer liaisons” trained internally. As a result, sales to external customers in the Pharmaceutical Wholesale Business segment were ¥533,412 million, and segment profit was ¥3,164 million.」
Regarding specialty pharmaceuticals, the Company describes its focus on hospital sales centred on cancer liaisons, together with the segment’s sales and profit results. - FY2019First statedAnnual report
「Response to Specialty Drugs」
The Company has identified practical challenges in addressing specialty pharmaceuticals, including orphan drugs and biopharmaceuticals.